share_log

中國生物製藥：翌日披露報表

SINO BIOPHARM: NEXT DAY DISCLOSURE RETURN

Hong Kong Stock Exchange ·  Apr 16 16:35
Summary by Futu AI
中國生物製藥有限公司（簡稱「中國生物製藥」）於2024年4月16日提交了翌日披露報表，披露公司股份購回情況。根據報表，中國生物製藥在同日購回了5,000,000股普通股，佔其於購回前已發行股份的0.027%。購回的股份每股價格為2.54港元，總計耗資12,700,000港元。該次股份購回後，公司的已發行股本維持在18,801,217,230股。公司確認，此次股份購回符合香港聯合交易所有限公司證券上市規則的相關規定，並且所有必要的法律文件已經正式存檔。此外，自普通決議案通過至今，公司在香港聯交所總共購回了13,000,000股，佔已發行股份的0.069%。
中國生物製藥有限公司（簡稱「中國生物製藥」）於2024年4月16日提交了翌日披露報表，披露公司股份購回情況。根據報表，中國生物製藥在同日購回了5,000,000股普通股，佔其於購回前已發行股份的0.027%。購回的股份每股價格為2.54港元，總計耗資12,700,000港元。該次股份購回後，公司的已發行股本維持在18,801,217,230股。公司確認，此次股份購回符合香港聯合交易所有限公司證券上市規則的相關規定，並且所有必要的法律文件已經正式存檔。此外，自普通決議案通過至今，公司在香港聯交所總共購回了13,000,000股，佔已發行股份的0.069%。
China Biopharmaceuticals Limited (“China Biopharmaceuticals”) filed a next-day disclosure report on April 16, 2024, disclosing the repurchase of the Company's shares. According to the report, China Biopharmaceuticals repurchased 5,000,000 shares of ordinary shares on the same day, representing 0.027% of its shares issued prior to the repurchase. The repurchased shares were priced at HK$2.54 per share, with a total cost of HK$12,700,000. After the share buyback, the issued share capital of the company remained at 18,801,217,230 shares. The Company confirms that this share repurchase complies with the relevant requirements of the Listing Rules of the Stock Exchange of Hong Kong Limited and that all necessary legal documents have been formally archived. In addition, since the adoption of the Ordinary Resolution, the company has repurchased a total of 13,000,000 shares on the Hong Kong Stock Exchange, representing 0.069% of the issued shares.
China Biopharmaceuticals Limited (“China Biopharmaceuticals”) filed a next-day disclosure report on April 16, 2024, disclosing the repurchase of the Company's shares. According to the report, China Biopharmaceuticals repurchased 5,000,000 shares of ordinary shares on the same day, representing 0.027% of its shares issued prior to the repurchase. The repurchased shares were priced at HK$2.54 per share, with a total cost of HK$12,700,000. After the share buyback, the issued share capital of the company remained at 18,801,217,230 shares. The Company confirms that this share repurchase complies with the relevant requirements of the Listing Rules of the Stock Exchange of Hong Kong Limited and that all necessary legal documents have been formally archived. In addition, since the adoption of the Ordinary Resolution, the company has repurchased a total of 13,000,000 shares on the Hong Kong Stock Exchange, representing 0.069% of the issued shares.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.